-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target

Benzinga·09/24/2026 14:36:02
Diffusion vocale
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.